Please assess the completion status of the following clinical trial:

Trial Title: Open-Label Study of INO-4212 With or Without INO-9012, Administered IM or ID Followed by Electroporation in Healthy Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 13.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-50 years;~* Able to provide consent to participate and having signed an Informed Consent Form (ICF);~* Able and willing to comply with all study procedures;~* Women of child-bearing potential who are in a relationship that could result in pregnancy agree to either remain sexually abstinent, use medically effective contraception (oral contraception, barrier methods, spermicide, etc.) or have a partner who is sterile from enrollment to 3 months following the last injection; OR, sexually active men who are considered sexually fertile must agree to use either a barrier method of contraception during the study, and agree to continue the use for at least 3 months following the last injection, or have a partner who is permanently sterile or unable to become pregnant;~* Normal screening ECG or screening ECG with no clinically significant findings;~* Screening laboratory (Complete blood count (CBC), serum electrolytes, blood urea nitrogen (BUN), creatinine (Cr), glucose, ALT, CPK, urinalysis) grade 0-1 within 30 days prior to administration of study treatment;~* No history of clinically significant immunosuppressive or autoimmune disease.~Exclusion Criteria:~* Administration of an investigational compound either currently or within 30 days of first dose;~* Previous receipt of an investigational product in an interventional trial for the treatment or prevention of Ebola (exceptions: verified receipt of placebo only or participation in an observational study);~* History of or positive serologic test for HIV, hepatitis B surface antigen (HBsAg); or any potentially communicable infectious disease as determined by the Principal Investigator or Medical Monitor;~* Positive serologic test for hepatitis C (exception: successful treatment with confirmation of sustained virologic response);~* Baseline creatinine greater than 1.5 (CKD Stage II or greater);~* Chronic liver disease or cirrhosis;~* Immunosuppressive illness including hematologic malignancy, history of solid organ or bone marrow transplantation;~* Any pre-excitation syndromes, e.g., Wolff-Parkinson-White syndrome;~* Prior major surgery or radiation therapy within 4 weeks of randomization;~* Pregnant, breast feeding, or considering becoming pregnant;~* Less than two acceptable sites exist for intramuscular or intradermal injection and EP between use of the deltoid and lateral quadriceps muscles. A site for injection/EP is not acceptable if there are tattoos, keloids or hypertrophic scars within 2 cm of the injection/EP site.~* Subject has significant acute or chronic medical illness if deemed by the practitioner that electroporation treatment could negatively impact the illness~* Subject has unstable or life-threatening cardiac disease (e.g. unstable angina, class 3 or higher congestive heart failure)~* Subject has an acute or chronic bleeding or clotting disorder that would contraindicate IM injections or use of blood thinners (e.g. anticoagulants or antiplatelet drugs) within 2 weeks;~* Subject has a cardioverter-defibrillator or pacemaker (to prevent a life-threatening arrhythmia) that is located ipsilateral to the intended deltoid injection site (unless deemed acceptable by a Cardiologist);~* Subject has metal implant or implantable medical device within the electroporation area;~* Administration of any vaccine within 4 weeks of first dose;~* Administration of any blood product within 3 months of first dose;~* Current or anticipated concomitant immunosuppressive therapy (excluding inhaled, topical skin and/or eye drop-containing corticosteroids, or low-dose methotrexate). Systemic corticosteroids must be discontinued at least 4 weeks prior to first dose;~* Current or anticipated treatment with TNF-α inhibitors such as infliximab, adalimumab, etanercept;~* Active military service personnel;~* Prisoner or subjects who are compulsorily detained (involuntary incarceration) for treatment of either a physical or psychiatric illness;~* Active drug or alcohol use or dependence that, in the opinion of the investigator, would interfere with adherence to study requirements or assessment of immunologic endpoints; or~* Any illness or condition that in the opinion of the investigator may affect the safety of the subject or the evaluation of any study endpoint.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Group 1 (Type: EXPERIMENTAL): INO-4201 IM + EP, 2 mg, 3 doses
- Group 2 (Type: EXPERIMENTAL): INO-4202 IM + EP, 2 mg, 3 doses
- Group 3 (Type: EXPERIMENTAL): INO-4201 ID + EP 0.2A, 2 mg, 3 doses
- Group 4 (Type: EXPERIMENTAL): INO-4212 IM + EP, 4 mg, 3 doses
- Group 5 (Type: EXPERIMENTAL): INO-4212 + INO-9012 IM + EP, 4+1 mg, 3 doses
- Group 6 (Type: EXPERIMENTAL): INO-4201 ID + EP 0.2A, 1 mg, 3 doses
- Group 7 (Type: EXPERIMENTAL): INO-4201 ID + EP 0.2A, 2 mg, 2 doses
- Group 8 (Type: EXPERIMENTAL): INO-4201 ID + EP 0.2A, 1 mg, 2 doses
- Group 9 (Type: EXPERIMENTAL): INO-4201 + INO-9012 ID + EP 0.2A, 1.6 + 0.4 mg, 3 doses
- Group 10 (Type: EXPERIMENTAL): INO-4201 + INO-9012 ID + EP 0.2A, 1.6 + 0.4 mg, 2 doses
- Group 11 (Type: EXPERIMENTAL): INO-4201 + INO-9012 ID + EP 0.2A, 0.8 + 0.2 mg, 3 doses
- Part II: Group 3A (Type: EXPERIMENTAL): INO-4201 ID + EP 0.2A, 2 mg, 3 doses
- Part II: Group 3B (Type: EXPERIMENTAL): INO-4201 ID + EP 0.1A, 2 mg, 3 doses

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete